Evidence map›Paper›PMID 42436321›Full record

ArticleBritish journal of cancer2026

TP53 mutation-biased CD8

Xiaohe Su, Kaifeng Jin, Han Zeng, Zhaopei Liu, Lingkai Zhang, Yawei Ding, Jiaxing Sun, Yuzhen Wu, Hailong Liu, Yuan Chang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xiaohe Su *Shanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Kaifeng Jin *Shanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0001-9867-6516
Han ZengDepartment of Urology, Urologic Surgery Center, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China.ORCID http://orcid.org/0000-0001-6486-2038
Zhaopei LiuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0002-5288-5037
Lingkai ZhangShanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yawei DingDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jiaxing SunDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Yuzhen WuDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hailong LiuDepartment of Urology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuan ChangDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-2042-9317
Le XuDepartment of Urology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.ORCID http://orcid.org/0000-0003-3494-3114
Zewei WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Yu ZhuDepartment of Urology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jiejie XuShanghai Urothelial Carcinoma Research Group (SUCRG), National Health Commission Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China. jjxufdu@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7431-9063

Funding

China Postdoctoral Science Foundation 2025M781936China Postdoctoral Science Foundation BX20230091National Natural Science Foundation of China (National Science Foundation of China) 82103408National Natural Science Foundation of China (National Science Foundation of China) 82272786National Natural Science Foundation of China (National Science Foundation of China) 82272930National Natural Science Foundation of China (National Science Foundation of China) 82372793Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 20224Y0232Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 202340127Shanghai Municipal Health Bureau (Shanghai Municipal Public Health Bureau) 202340195
6 · The paper itself

Abstract

backgroundEmerging evidence has underscored non-cell-autonomous roles of mutant p53 in reshaping the composition and functional state of tumour immune microenvironment (TIME). However, the impact of p53 status on the clinical relevance and functional differentiation of CD8

methodsOur study included 297 UC patients from two in-house cohorts and 871 UC patients from four public datasets to evaluate the impact of p53 status on the clinical implications of CD8

resultsHigh CD8

conclusionsThe clinical significance and functional polarisation of CD8

Indexed as

Carcinoma, Transitional CellCD8-Positive T-LymphocytesDrug Resistance, NeoplasmTumor Suppressor Protein p53Urinary Bladder NeoplasmsAgedFemaleHepatitis A Virus Cellular Receptor 2HumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedMutationPrognosisT-Cell ExhaustionTumor MicroenvironmentHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2TP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID42436321
PMCPMC13578338

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.